% alzhub.org library filter
% Source: https://alzhub.org/research?author=Shcherbinin+S&design=trial
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{mintun2021-33720637,
  author  = {Mintun, M. A. and Lo, A. C. and Duggan Evans, C. and Wessels, A. M. and Ardayfio, P. A. and Andersen, S. W. and Shcherbinin, S. and Sparks, J. and others},
  title   = {{Donanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2021},
  doi     = {10.1056/nejmoa2100708},
  pmid    = {33720637},
  url     = {https://doi.org/10.1056/nejmoa2100708}
}

@article{wang2025-40172303,
  author  = {Wang, H. and Serap Monkul Nery, E. and Ardayfio, P. and Khanna, R. and Otero Svaldi, D. and Gueorguieva, I. and Shcherbinin, S. and Andersen, S. W. and Hauck, P. M. and Engle, S. E. and others},
  title   = {{Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70062},
  pmid    = {40172303},
  url     = {https://doi.org/10.1002/alz.70062}
}

@article{lu2025-41082199,
  author  = {Lu, M. and Kim, M. J. and Collins, E. C. and Shcherbinin, S. and Ellinwood, A. K. and Yokoi, Y. and Brooks, D. A. and Hansson, O. and others},
  title   = {{Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2025},
  doi     = {10.1001/jamaneurol.2025.3869},
  pmid    = {41082199},
  url     = {https://doi.org/10.1001/jamaneurol.2025.3869}
}

@article{shcherbinin2022-36094645,
  author  = {Shcherbinin, S. and Evans, C. D. and Lu, M. and Andersen, S. W. and Pontecorvo, M. J. and Willis, B. A. and Gueorguieva, I. and Hauck, P. M. and others},
  title   = {{Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2793},
  pmid    = {36094645},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2793}
}

@article{sims2023-9857475c,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  pmid    = {37459141}
}

@article{sims2023-37459141,
  author  = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and others},
  title   = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
  journal = {JAMA},
  year    = {2023},
  doi     = {10.1001/jama.2023.13239},
  pmid    = {37459141},
  url     = {https://doi.org/10.1001/jama.2023.13239}
}